litlas
ログインアカウント作成

PierFranco Conte

1986–2025 年に発表

別表記
Pierfranco Conte
196
論文数
37,062
被引用数
95
h 指数
193
i10 指数

被引用数

PierFranco Conte の年別被引用数1964 年: 被引用 2 件1982 年: 被引用 1 件1987 年: 被引用 5 件1989 年: 被引用 3 件1990 年: 被引用 4 件1991 年: 被引用 4 件1992 年: 被引用 4 件1993 年: 被引用 12 件1994 年: 被引用 4 件1995 年: 被引用 10 件1996 年: 被引用 13 件1997 年: 被引用 19 件1998 年: 被引用 46 件1999 年: 被引用 26 件2000 年: 被引用 36 件2001 年: 被引用 60 件2002 年: 被引用 59 件2003 年: 被引用 57 件2004 年: 被引用 76 件2005 年: 被引用 77 件2006 年: 被引用 87 件2007 年: 被引用 102 件2008 年: 被引用 86 件2009 年: 被引用 107 件2010 年: 被引用 118 件2011 年: 被引用 128 件2012 年: 被引用 128 件2013 年: 被引用 141 件2014 年: 被引用 107 件2015 年: 被引用 117 件2016 年: 被引用 150 件2017 年: 被引用 195 件2018 年: 被引用 268 件2019 年: 被引用 1,011 件2020 年: 被引用 1,496 件2021 年: 被引用 1,710 件2022 年: 被引用 1,469 件2023 年: 被引用 1,299 件2024 年: 被引用 1,830 件2025 年: 被引用 898 件2026 年: 被引用 28 件1965〜1981 年は被引用が無いため表示していません1983〜1986 年は被引用が無いため表示していません1988 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,660 件、この内訳の 22.5%中国: 引用元論文 1,507 件、この内訳の 9.3%イタリア: 引用元論文 1,348 件、この内訳の 8.3%イギリス: 引用元論文 980 件、この内訳の 6%ドイツ: 引用元論文 801 件、この内訳の 4.9%スペイン: 引用元論文 756 件、この内訳の 4.6%フランス: 引用元論文 751 件、この内訳の 4.6%カナダ: 引用元論文 528 件、この内訳の 3.2%日本: 引用元論文 524 件、この内訳の 3.2%オーストラリア: 引用元論文 414 件、この内訳の 2.5%ベルギー: 引用元論文 408 件、この内訳の 2.5%オランダ: 引用元論文 396 件、この内訳の 2.4%
0%22.5%その他 26%

機関

分野

  • Medicine71.6%
  • Biochemistry, Genetics and Molecular Biology23.1%
  • Immunology and Microbiology1.2%
  • Computer Science0.7%
  • Engineering0.6%
  • Materials Science0.6%
  • その他2.2%

トピック

  • Advanced Breast Cancer Therapies7.3%
  • HER2/EGFR in Cancer Research6.1%
  • Breast Cancer Treatment Studies5.2%
  • Cancer Immunotherapy and Biomarkers4%
  • PARP inhibition in cancer therapy3.3%
  • Cancer Genomics and Diagnostics3.3%
  • その他70.8%

共著者

全論文

検索で開く
  1. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    著者: Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, PierFranco Conte, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric - New England Journal of Medicine 2019 被引用: 2,572

  2. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    著者: Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wěi Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, PierFranco Conte - New England Journal of Medicine 2017 被引用: 3,214

  3. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

    著者: Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice André, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy - New England Journal of Medicine 2022 被引用: 713

  4. openalex_id:w4221085715

    著者: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Lowell L. Hart, Mario Campone, Katarína Petráková, Eric P. Winer, Wolfgang Janni, PierFranco Conte, David Cameron, Fabrice André, Carlos L. Arteaga, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy 被引用: 579

  5. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    著者: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 被引用: 2,009

  6. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

    著者: George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, PierFranco Conte, Yi Lu, Susana Barriga, Karla Hurt, Martin Frenzel, Stephen Johnston, Antonio Llombart‐Cussac - JAMA Oncology 2019 被引用: 987

  7. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    著者: Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le - New England Journal of Medicine 2020 被引用: 854

  8. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    著者: Fabrice André, Eva Ciruelos, Dejan Juric, Sibylle Loibl, Mario Campone, Ingrid A. Mayer, Gábor Rubovszky, Toshinari Yamashita, Bella Kaufman, Yen‐Shen Lu, Kenichi Inoue, Zsuzsanna Pápai, Masato Takahashi, Farhat Ghaznawi, David Mills, Mathilde Kaper, Michelle C. Miller, PierFranco Conte, Hiroji Iwata, Hope S. Rugo - Annals of Oncology 2020 被引用: 599

  9. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

    著者: Gabriel N. Hortobágyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, M. Campone, Katarína Petráková, Kimberly Blackwell, Eric P. Winer, W Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, S. Mondal, Fei Su, Marshall G. Miller, Mohamed Elmeliegy, Caroline Germa, Joyce O’Shaughnessy - Annals of Oncology 2018 被引用: 868

  10. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    著者: Mark E. Robson, Nadine Tung, PierFranco Conte, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Norikazu Masuda, Suzette Delaloge, W. Li, Anne Armstrong, Weiwen Wu, Carsten Goessl, Sarah Runswick, Susan M. Domchek - Annals of Oncology 2019 被引用: 760

  11. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

    著者: Hans von der Maase, Steen Werner Hansen, J.T. Roberts, Luigi Dogliotti, T. Oliver, Malcolm J. Moore, I. Bodrogi, Peter Albers, Alexander Knuth, Christian Lippert, Pierre Kerbrat, Pedro Sánchez‐Rovira, Peter Wersäll, Simon Cleall, D. Roychowdhury, Irene Tomlin, Carla Visseren‐Grul, PierFranco Conte - Journal of Clinical Oncology 2000 被引用: 2,286

  12. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

    著者: Aleix Prat, Valentina Guarneri, Tomás Pascual, Fara Brasó‐Maristany, Esther Sanfeliu, Laia Paré, Francesco Schettini, Débora Martínez, Pedro Jares, Gaia Griguolo, Maria Vittoria Dieci, Javier Cortés, Antonio Llombart‐Cussac, Benedetta Conte, Mercedes Marín‐Aguilera, Núria Chic, Joan Anton Puig‐Butillé, Antonio Martı́nez, Patricia Galván, Yi‐Hsuan Tsai, Blanca González‐Farré, Áurea Mira, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, PierFranco Conte, Charles M. Perou - EBioMedicine 2022 被引用: 145

  13. Evolution of HER2-low expression from primary to recurrent breast cancer

    著者: Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Maria Vernaci, Ottavia Amato, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci - npj Breast Cancer 2021 被引用: 226

  14. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

    著者: PierFranco Conte, P.A. Ascierto, Giorgio Patelli, Romano Danesi, Angelo Vanzulli, Fabio Sandomenico, Paolo Tarsia, Anna Maria Cattelan, Alessia Comes, Michelino De Laurentiis, Alfredo Falcone, Daniele Regge, Luca Richeldi, Salvatore Siena - ESMO Open 2022 被引用: 214

  15. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management

    著者: Sandra M. Swain, Mizuki Nishino, Lisa Lancaster, Bob T. Li, Andrew G. Nicholson, Brian J. Bartholmai, Jarushka Naidoo, Eva Schumacher-Wulf, Kohei Shitara, Junji Tsurutani, PierFranco Conte, Terufumi Kato, Fabrice André, Charles A. Powell - Cancer Treatment Reviews 2022 被引用: 167

  16. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    著者: Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, S Stanzel, Alexander Strasak, Monika Patre, Paul Ellis - Journal of Clinical Oncology 2017 被引用: 413

  17. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

    著者: Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, PierFranco Conte, Véronique Dièras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders - Clinical Cancer Research 2020 被引用: 198

  18. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    著者: Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, A. Allen, PierFranco Conte - European Journal of Cancer 2023 被引用: 111

  19. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

    著者: Hope S. Rugo, Fabrice André, Toshinari Yamashita, Humberto Cerda, I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, PierFranco Conte, Mario Campone, C. Wilke, David Mills, Agnes Lteif, Michelle C. Miller, Fiorenza Gaudenzi, Sibylle Loibl - Annals of Oncology 2020 被引用: 187

  20. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    著者: Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, Marc Espié, Sibel Blau, Antoinette R. Tan, Steven J. Isakoff, Mafalda Oliveira, Cristina Saura, Matthew Wongchenko, Amy V. Kapp, Wai Yee Chan, Stina Mui Singel, Daniel Maslyar, José Baselga, Sungbae Kim, Keun Seok Lee, Seock‐Ah Im, Marc Espié, Hwei-Chung Wang, Sibel Blau, Rebecca Dent, Antoinette R. Tan, Joohyuk Sohn, Michelino De Laurentiis, Laura García‐Estévez, Chiun‐Sheng Huang, Gilles Romieu, Michel Velez, Rafael Villanueva-Vázquez, PierFranco Conte, Shaker R. Dakhil, Marc Debled, Antonio González-Martı́n, Sara A. Hurvitz, Jee Hyun Kim, Christelle Lévy, Mafalda Oliveira, Pedro Sánchez‐Rovira, Jae Hong Seo, Vicente Valero, Gregory A. Vidal, Andrea Wong, Mary Ann Allison, Robert A. Figlin, David Chan, Shin‐Cheh Chen, Yen‐Hsun Chen, Melody Cobleigh, Filippo de Braud, Luc Dirix, Vincent Hansen, Anne Hardy Bessard, Nicholas Iannotti, Steven J. Isakoff, William Lawler, Álvaro Montaño, Mohamad Salkini, L. Seigel - The Lancet Oncology 2017 被引用: 474

  21. Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial

    著者: Maria Vittoria Dieci, Valentina Guarneri, Anna Tosi, Giancarlo Bisagni, Antonino Musolino, Simon Spazzapan, Gabriella Moretti, Grazia Maria Vernaci, Gaia Griguolo, Tommaso Giarratano, Loredana Urso, Francesca Schiavi, Claudia Pinato, Giovanna Magni, Marcello Mele, Gian Luca De Salvo, Antonio Rosato, PierFranco Conte - Clinical Cancer Research 2021 被引用: 115

  22. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

    著者: Francesco Schettini, Tomás Pascual, Benedetta Conte, Núria Chic, Fara Brasó‐Maristany, Patricia Galván, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Montserrat Muñoz-Mateu, Aranzazu Fernández-Martínez, Carla Rognoni, Gaia Griguolo, Valentina Guarneri, PierFranco Conte, Mariavittoria Locci, Jan C. Brase, Blanca González‐Farré, Patricia Villagrasa, Sabino De Placido, Rachel Schiff, Jamunarani Veeraraghavan, Mothaffar F. Rimawi, C. Kent Osborne, Sònia Pernas, Charles M. Perou, Lisa A. Carey, Aleix Prat - Cancer Treatment Reviews 2020 被引用: 185

  23. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

    著者: Marion van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E. Geyer, Luca Gianni, Andreas Schneeweiß, PierFranco Conte, Martine Piccart, Hervé Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard D. Gelber, Coralie Poncet, Pierre Squifflet, Everardo D. Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortés, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar, on behalf of the CTNeoBC project - Journal of Clinical Oncology 2023 被引用: 96

  24. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

    著者: Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso, Ilaria Attili, Paola Del Bianco, Giulia Pasello, Valentina Guarneri, Giuseppe Aprile, PierFranco Conte, Laura Bonanno - The Oncologist 2019 被引用: 228